Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 4 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Acromegaly 2Pituitary Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neoplasms 1Gigantism 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Octreotide 4lanreotide 3Everolimus 3Carboplatin 2surufatinib 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Cisplatin 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Neuroendocrine Tumors × lanreotide × Clear all
NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT02075606 2019-06-07

CALM-NET

Ipsen

Phase 4 Completed
50 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT03083210 2019-05-20

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Center

Phase 4 Unknown
28 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡